Progen to begin myeloma Phase II

Progen (PGLAF; ASX:PGL) will begin a Phase II trial in Australia of its PI-88 sulfated mannopentaose phosphate to treat relapsed or refractory multiple myeloma. PI-88 is in Phase I/II testing for adva...